Could Eiger Biopharmaceuticals Inc (EIGR) Rise Even More? The Stock Had Another Big Increase Today

September 17, 2017 - By Winifred Garcia

The stock of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) is a huge mover today! The stock increased 6.19% or $0.65 on September 15, reaching $11.15. About 60,942 shares traded or 6.85% up from the average. Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) has declined 64.64% since September 17, 2016 and is downtrending. It has underperformed by 81.34% the S&P500.
The move comes after 8 months positive chart setup for the $93.29M company. It was reported on Sep, 17 by Barchart.com. We have $11.60 PT which if reached, will make NASDAQ:EIGR worth $3.73 million more.

Analysts expect Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) to report $-1.26 EPS on November, 14.They anticipate $0.23 EPS change or 15.44 % from last quarter’s $-1.49 EPS. After having $-1.33 EPS previously, Eiger Biopharmaceuticals Inc’s analysts see -5.26 % EPS growth.

More notable recent Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) news were published by: Prnewswire.com which released: “Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon …” on October 19, 2016, also Prnewswire.com with their article: “Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study …” published on July 25, 2016, Seekingalpha.com published: “Eiger Biopharmaceuticals: Can This $10 Biotech Stock Continue To Rally?” on July 18, 2017. More interesting news about Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) were released by: Marketwatch.com and their article: “11.15” published on March 24, 2016 as well as Seekingalpha.com‘s news article titled: “Eiger BioPharmaceuticals: Another Cheap Bio-Catalyst Play” with publication date: March 21, 2017.

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The company has market cap of $93.29 million. The Firm is focused on the development and commercialization of products for the treatment of orphan diseases. It currently has negative earnings. The Company’s pipeline includes Sarasar for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: